Tenax Therapeutics (NASDAQ:TENX) Posts Earnings Results

Tenax Therapeutics (NASDAQ:TENX) issued its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, FiscalAI reports.

Here are the key takeaways from Tenax Therapeutics’ conference call:

• Tenax announced it hit its enrollment target of 230 PH‑HFpEF patients for LEVEL ahead of plan, expects to complete randomization in March, and now narrows topline timing to Q3 for the 12‑week readout.
• Management reports strong trial engagement — consumption/compliance on the TID oral regimen is very high and >90% of patients enter the open‑label extension — suggesting favorable tolerability and retention.
• A blinded sample‑size reassessment showed the six‑minute‑walk standard deviation is lower than the conservative assumption, materially increasing the study’s power to >90% without changing the planned statistical approach.
• Executives emphasized a clear mechanistic proof‑of‑concept for oral levosimendan — splanchnic dilation/volume redistribution — supported by HELP phase II hemodynamics and comparable effects seen with invasive splanchnic block/vena cava device data, with accompanying functional improvement signals.
• LEVEL‑2 will be a larger, global 26‑week study (roughly double the subjects) across multiple regions; management expects multi‑year enrollment and plans to continue building safety data before pursuing regulatory discussions or submissions.

Tenax Therapeutics Trading Up 31.7%

NASDAQ:TENX opened at $14.51 on Wednesday. The stock’s 50-day moving average is $13.21 and its 200-day moving average is $9.84. Tenax Therapeutics has a 1-year low of $4.63 and a 1-year high of $18.38. The stock has a market cap of $90.54 million, a P/E ratio of -12.84 and a beta of 1.41.

Institutional Trading of Tenax Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Corient Private Wealth LLC acquired a new position in Tenax Therapeutics during the 4th quarter worth about $151,000. Sphera Funds Management LTD. acquired a new stake in shares of Tenax Therapeutics in the fourth quarter valued at about $2,317,000. Quadrature Capital Ltd bought a new position in shares of Tenax Therapeutics during the fourth quarter worth about $252,000. Perceptive Advisors LLC bought a new position in shares of Tenax Therapeutics during the fourth quarter worth about $5,353,000. Finally, Artia Global Partners LP acquired a new position in shares of Tenax Therapeutics in the fourth quarter worth approximately $513,000. 1.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TENX has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Tenax Therapeutics in a report on Monday, December 22nd. Guggenheim reiterated a “buy” rating and set a $25.00 price objective (up from $14.00) on shares of Tenax Therapeutics in a research report on Wednesday, December 17th. Finally, William Blair restated an “outperform” rating on shares of Tenax Therapeutics in a research report on Tuesday. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.